Alzheimer's disease is characterized by the deposition of amyloid-b peptide in the brain. N-terminal truncation resulting in the formation of Ab N3pE and phosphorylation at serine 8 have been reported to modify aggregation properties of amyloid-b. Biochemically, soluble, dispersible, membrane-associated, and insoluble, plaque-associated amyloid-b aggregates have been distinguished. Soluble and dispersible amyloid-b aggregates are both in mixture with the extracellular or intracellular fluid but dispersible aggregates can be cleared from proteins in solution by ultracentrifugation. To clarify the role of phosphorylated amyloid-b and Ab N3pE in soluble, dispersible, membrane-associated, and plaque-associated amyloid-b aggregates in the pathogenesis of Alzheimer's disease we studied brains from 21 cases with symptomatic Alzheimer's disease, 33 pathologically preclinical Alzheimer's disease cases, and 20 control cases. Western blot analysis showed that soluble, dispersible, membrane-associated and plaque-associated amyloid-b aggregates in the earliest preclinical stage of Alzheimer's disease did not exhibit detectable amounts of Ab N3pE and phosphorylated amyloid-b. This stage was referred to as biochemical stage 1 of amyloid-b aggregation and accumulation. In biochemical amyloid-b stage 2, Ab N3pE was additionally found whereas phosphorylated amyloid-b was restricted to biochemical amyloid-b stage 3, the last stage of amyloid-b aggregation. Phosphorylated amyloid-b was seen in the dispersible, membrane-associated, and plaque-associated fraction. All cases with symptomatic Alzheimer's disease in our sample fulfilled biochemical amyloid-b stage 3 criteria, i.e. detection of phosphorylated amyloid-b. Most, but not all, cases with pathologically preclinical Alzheimer's disease had biochemical amyloid-b stages 1 or 2. Immunohistochemistry confirmed the hierarchical occurrence of amyloid-b, Ab N3pE , and phosphorylated amyloid-b in amyloid plaques. Phosphorylated amyloid-b containing plaques were, thereby, seen in all symptomatic cases with Alzheimer's disease but only in a few non-demented control subjects. plaque deposition and with that of neurofibrillary tangle pathology. Taken together, we demonstrate that Ab N3pE and phosphorylated amyloid-b are not only detectable in plaques, but also in soluble and dispersible amyloid-b aggregates outside of plaques. They occur in a hierarchical sequence that allows the distinction of three stages. In light of our findings, it is tempting to speculate that this hierarchical, biochemical sequence of amyloid-b aggregation and accumulation is related to disease progression and may be relevant for an increasing toxicity of amyloid-b aggregates.
Introduction
Alzheimer's disease is characterized by the formation of amyloid-b (Ab) protein aggregates in the brain (Alzheimer, 1907; Masters et al., 1985; Hyman et al., 2012) . Various types of Ab aggregates have been described: soluble Ab oligomers, dispersible Ab oligomers, protofibrils and fibrils, membrane-associated (SDS soluble) Ab aggregates, and solid, plaque-associated (formic acid soluble) Ab fibrils (Harper et al., 1997; Walsh et al., 1997; Kayed et al., 2003; Lesne et al., 2006; Habicht et al., 2007; Shankar et al., 2008; Rijal Upadhaya et al., 2012a) . Recently, we showed that dispersible Ab oligomers, protofibrils, and fibrils are pathologically relevant forms of Ab aggregates that cause neurotoxic effects in a concentration-dependent manner as demonstrated in APP transgenic mouse models (Rijal Upadhaya et al., 2012a) . Dispersible Ab aggregates represent diffusible but non-soluble Ab aggregates that differ from insoluble membrane-associated and plaque-associated Ab aggregates. In contrast to plaque-associated and membraneassociated Ab, dispersible Ab is thought to represent not fully dissolved Ab aggregates mixed with the extra-or intracellular fluid whereas membrane-associated and plaque-associated Ab are not mixed with the extracellular fluid and become detectable only after SDS or formic acid treatment. Dispersible Ab can be separated from soluble Ab by ultracentrifugation (Rijal Upadhaya et al., 2012a) . Currently, it is not clear whether dispersible Ab aggregates play a role in the human Alzheimer's disease brain.
Post-translational N-terminal truncation of the first two amino acids of the Ab peptide and subsequent pyroglutamate formation at the N-terminal glutamate resulting in Ab N3pE (Saido et al., 1995) as well as phosphorylation of serine 8 of Ab (Kumar et al., 2011) have been described. Both Ab N3pE and phosphorylated Ab occur in Alzheimer's disease plaques (Saido et al., 1995; Kumar et al., 2011) . Ab N3pE increases the aggregation propensity of Ab by changing the biophysical properties of Ab fibrils (Schlenzig et al., 2009) . Phosphorylated Ab, on the other hand, promotes the formation of Ab oligomers that serve as nucleation sites for fibril formation (Kumar et al., 2011) . Here, it is suggested that these modifications of Ab play a role in Alzheimer's disease pathogenesis and the development of dementia, but it is not clear at which stage of the disease and in which types of aggregates these modifications may become evident.
Alzheimer's disease begins many years before the cognitive deficits become evident that allow its clinical diagnosis. The recently revised criteria for the clinical diagnosis of Alzheimer's disease introduced preclinical Alzheimer's disease as a diagnosis for non-demented individuals with positive biomarkers for Alzheimer's disease, e.g. Alzheimer's disease-like Pittsburg compound B retention in the brain (Dubois et al., 2007; Sperling et al., 2011) . Current neuropathological guidelines for the assessment of Alzheimer's disease pathology recommend the description of the level of Alzheimer's disease pathology in a given brain regardless of the ante-mortem cognitive status (Hyman et al., 2012) . As such, by employing the neuropathological diagnosis of Alzheimer's disease pathology as a biomarker for Alzheimer's disease, pathologically preclinical Alzheimer's disease cases are those that were non-demented before death, but exhibit at least low levels of Alzheimer's disease pathology at autopsy, whereas symptomatic Alzheimer's disease cases exhibit significant Alzheimer's disease pathology and cognitive impairment (Monsell et al., 2013) . Non-Alzheimer's disease cases are those without any Ab plaques (Hyman et al., 2012) . The term 'pathologically preclinical Alzheimer's disease' for non-demented cases with amyloid plaques does not necessarily mean that these cases must convert into symptomatic Alzheimer's disease. It cannot be excluded that progression of pathology may cease in some of these cases although they fulfil the recommended criteria for low levels of Alzheimer's disease pathology. Whether the biochemical composition of cortical Ab aggregates has impact on the course of the disease and the development of dementia is not yet clear. Clinical criteria for preclinical Alzheimer's disease based on CSF-Ab and CSF-tau protein levels have been published (Vos et al., 2013) that differ from the neuropathological definition of pathologically preclinical Alzheimer's disease that is used here, synonymous with the term 'asymptomatic Alzheimer's disease' (Monsell et al., 2013) .
To clarify the role of phosphorylation of Ab and Ab N3pE formation for the clinicopathological stage of the disease and for the pattern of Ab aggregate types, we studied brains from 21 patients with Alzheimer's disease, 33 with pathologically preclinical Alzheimer's disease, and 20 non-demented control cases immunohistochemically and biochemically.
Materials and methods

Neuropathology
For morphological analysis, autopsy brains from 21 patients with Alzheimer's disease, 20 control cases without any Ab-pathology and 33 cases with pathologically preclinical Alzheimer's disease were used (Tables 1 and 2 ). None of the investigated cases had a known familial background for Alzheimer's disease. After autopsy, brains were fixed in a 4% aqueous solution of formaldehyde. Following fixation the medial temporal lobe and tissue from the occipital cortex containing the primary visual field were embedded in paraffin. Further medial temporal lobe tissue of the cases listed in Table 1 was embedded in polyethylene glycol. Paraffin sections were cut at 12 mm, polyethylene glycol sections at 100 mm. Histopathological diagnosis of Alzheimer's disease was performed by analysing Gallyas, Campbell-Switzer, antiabnormal tau-protein (anti-PHF-) and anti-Ab 17-24 stained sections of the medial temporal lobe and the occipital cortex (Supplementary Table 1 ). Braak neurofibrillary tangle staging and the assignment of Consortium to Establish a Registry for Alzheimer's Disease (CERAD) scores for neuritic plaque density were performed on the basis of the Gallyas-stained and anti-PHF--stained sections (Braak and Braak, 1991; Mirra et al., 1991; Braak et al., 2006; Alafuzoff et al., 2008) . The distribution of amyloid plaques in the medial temporal lobe (Abmedial temporal lobe phase) had been obtained according to previously published criteria (Thal et al., 2000) and represents the distribution of Ab plaques in the human brain as a semi-quantitative parameter for the overall severity of Ab plaque pathology (Thal et al., 2002) . Ab-medial temporal lobe phase, Braak-neurofibrillary tangle stages and CERAD scores for neuritic plaques were used to determine the degree of Alzheimer's disease pathology according to recently published guidelines (Hyman et al., 2012) .
The cases had usually been examined 1 to 4 weeks before death by different clinicians according to standardized protocols. The protocols included the assessment of cognitive function and recorded the ability 1  A23  88  M  p-preAD, AGD  2  3  2  1  Low  3  A24  78  M  AD  1  3  4  1  Intermediate 3  A25  68  F  AD  1  4  6  3  High  3  A26  82  M  AD  2  3  3  2  Intermediate 3  A27  89  F  AD  2  4  4  3  Intermediate 3  A28  87  F  AD  3  4  4  1  Intermediate 3  A29  83  M  AD  3  4  4  2  Intermediate 3  A30  81  F  AD  3  4  5  1  Intermediate 3  A31  89  F  AD  3  4  5  2  High  3  A32  78  F  AD  3  4  5  3  High  3  A33  83  M  AD  3  4  5  3  High  3  A34  86  F  AD, AGD  3  4  6  3  High  3 Age in years. Clinical dementia rating (CDR) scores (Morris, 1993) , Ab-MTL phase (Thal et al., 2000) , Braak-neurofibrillary tangle stage (Braak et al., 2006) , CERAD score for neuritic plaque density (Mirra et al., 1991) , and the degree of Alzheimer's disease pathology (Hyman et al., 2012) were determined as previously published and recommended. The biochemical Ab stage was determined as depicted in Fig. 6 . M = male; F = female, (control) non-demented control; AD = Alzheimer's disease; AGD = argyrophilic grain disease; ALS = amyotrophic lateral sclerosis; CBD = corticobasal degeneration; FTLD-TDP = frontotemporal lobar degeneration with TDP43-pathology; MCI (AD) = mild cognitive impairment with predominant Alzheimer's disease pathology; MTL = medial temporal lobe; n.d. = not done; NIA-AA AD degree = Degree of Alzheimer's disease pathology (Hyman et al., 2012) ; NFT = neurofibrillary tangle; NMO = neuromyelitis optica; p-preAD = pathologically diagnosed preclinical Alzheimer's disease; VD = vascular dementia.
to care for and dress oneself, eating habits, bladder and bowel continence, speech patterns, writing and reading, short-term and long-term memory, and orientation within the hospital setting. In the event that a Clinical Dementia Rating score could not be obtained because of missing clinical data, this is noted in Table 1 . These data were used to retrospectively assess Clinical Dementia Rating scores for each patient (Morris et al., 1989) . The diagnosis of symptomatic Alzheimer's disease including Alzheimer's disease-related mild cognitive impairment was considered for all individuals with a Clinical Dementia Rating score 50.5, which exhibited either an intermediate or high degree of Alzheimer's disease pathology according to the National Institute of Aging Alzheimer Association (NIA-AA) guidelines for the neuropathological diagnosis of Alzheimer's disease (Hyman et al., 2012) . Controls were defined by the absence of any Ab plaques. They either had no Age in years. Clinical dementia rating (CDR) scores (Morris, 1993) , Ab-medial temporal lobe phase (Thal et al., 2000) , Braak-neurofibrillary tangle stage (Braak et al., 2006) , CERAD score for neuritic plaque density (Mirra et al., 1991) , and the degree of Alzheimer's disease pathology (Hyman et al., 2012) were determined as previously published and recommended. The biochemical Ab stage was determined as depicted in Fig. 6 . M = male; F = female, (control) non-demented control; AD = Alzheimer's disease; AGD = argyrophilic grain disease; ALS = amyotrophic lateral sclerosis; CBD = corticobasal degeneration; FTLD-TDP = frontotemporal lobar degeneration with TDP43-pathology; MCI (AD) = mild cognitive impairment with predominant Alzheimer's disease pathology; MTL = medial temporal lobe; n.d. = not done; NIA-AA AD degree = Degree of Alzheimer's disease pathology (Hyman et al., 2012) ; NFT = neurofibrillary tangle; NMO = neuromyelitis optica; p-preAD = pathologically diagnosed preclinical Alzheimer's disease; VD = vascular dementia.
neurofibrillary tangles or not more than Braak-neurofibrillary tangle stage I. Non-demented cases with Ab plaques, i.e. having low or intermediate degrees of Alzheimer's disease pathology were categorized as cases with pathologically preclinical Alzheimer's disease. For biochemical analysis we used fresh-frozen occipital and temporal lobe tissue from 10 patients with Alzheimer's disease, 20 patients with pathologically preclinical Alzheimer's disease and 10 control subjects ( Table 2) .
The human brain tissue used in this study originated from the Brain Bank of the Laboratory of Neuropathology at the University of Ulm (Germany). This brain bank collects brain tissue in accordance with German legal regulations. The project was approved by the ethics committee of the University of Ulm.
Immunohistochemistry
Morphological and immunohistochemical analyses were carried out on cases shown in Table 1 and 2 (n = 73; Case B25 was not included because only frozen tissue was available). Paraffin sections from the human medial lobe and the occipital cortex were stained with antiAb 17-24 , anti-Ab 42 , anti-Ab N3pE , and anti-phosphorylated Ab (Kim et al., 1988; Saido et al., 1995; Yamaguchi et al., 1998; Kumar et al., 2011) 
Quantification of amyloid-b load
Ab load was determined as the percentage of the area in the temporal neocortex (Brodmann area 36) covered by Ab plaques detected with anti-Ab 17-24 . Morphometry for Ab load determination was performed using ImageJ image processing and analysis software (National Institutes of Health). For plaque measurements the area of the morphologically identified plaques was interactively delineated with a cursor and then measured by using the ImageJ software package (National Institutes of Health). The areas of all plaques in a given cortical region were added up. The area of the respective cortex areas was likewise measured by interactive delineation with a cursor. Accordingly, the Ab N3pE load was determined as the percentage of the temporal neocortex area covered by anti-Ab N3pE -positive plaques and the phosphorylated Ab load by that of anti-phosphorylated Ab-positive plaques.
Preparation of native human brain lysates
Biochemical analysis was carried out from cases shown in Table 2 . Protein extraction from fresh frozen brain (0.04 g) was carried out in 2 ml Tris-buffered saline containing a protease and phosphatase inhibitor-cocktail (Complete and PhosSTOP, Roche). The tissue was homogenized with Micropestle (Eppendorf) before sonication. The homogenate was centrifuged for 30 min at 14 000g at 4 C. The supernatant with the soluble and dispersible fraction not separated from one another was retained. The pellet containing the membrane-associated and the solid plaque-associated fraction was resuspended in 2% SDS (Fig. 1) . Ultracentrifugation of the supernatant at 175 000g was used to separate the soluble, i.e. the supernatant after ultracentrifugation, from the dispersible fraction, i.e. the resulting pellet (Fig. 1) . The pellet of the dispersible fraction was resuspended in TBS and stored at À80 C until further use. After separation from the soluble and the dispersible fraction, the SDS-resuspended pellet was centrifuged at 14 000g, and the supernatant was kept as membrane-associated SDS fraction (Fig. 1) . The pellet was further dissolved in 70% formic acid and the homogenate was lyophilized by centrifuging in the vacuum centrifuge (Vacufuge; Eppendorf) and reconstituted in 100 ml of 2Â lithium dodecyl sulphate sample buffer (Invitrogen) before heating at 70 C for 5 min. The resulting sample was considered as plaque-associated, formic acid-soluble fraction (Mc Donald et al., 2010) . The total protein amounts of soluble, dispersible, and membrane-associated fractions were determined using BCA Protein Assay (Bio-Rad).
Immunoprecipitation
For immunoprecipitation, 200 ml of the native soluble and dispersible fractions from the brain lysates were incubated with 1 ml A11 antibodies against non-fibrillar oligomers, B10AP antibody fragments for precipitation of protofibrils and fibrils, anti-Ab N3pE or anti-phosphorylated Ab at 4 C for 4 h as previously described (Rijal Upadhaya et al., 2012a) (Supplementary Table 1 ). Protein G Microbeads (50 ml; Miltenyi Biotec) were added to the mixture and incubated overnight at 4 C. The mixture was then passed through the m Columns which separate the microbeads by retaining them in the column, while the rest of the lysate flows through. After one mild washing step with TBS at pH 7.4 the microbead-bound proteins were eluted with 95 C heated lithium dodecyl sulphate sample buffer (Invitrogen). To verify specific precipitation of non-fibrillar oligomers with A11 and protofibrils and fibrils with B10AP and to exclude contamination with membrane-coated microsomes, precipitates were analysed for non-fibrillar oligomeric or protofibrillar/fibrillar protein structure by transmission electron microscopy as previously published (Rijal Upadhaya et al., 2012b) .
Western blot analysis
The four fractions (soluble, dispersible, membrane-associated and plaque-associated) as well as immunoprecipitation eluates were analysed by SDS-PAGE and subsequent western blot analysis with antiAb 1-17 , anti-phosphorylated Ab and anti-Ab N3pE antibodies (Supplementary Table 1 ). Ab 40 and Ab 42 were detected with C-terminus specific antibodies (Supplementary Table 1 ) after precipitation of Ab N3pE and phosphorylated Ab to clarify whether these post-translational modifications occur in both Ab peptides, Ab 40 and Ab 42 . Blots were developed with an ECL detection system (Supersignal Pico Western system, ThermoScientific-Pierce) and illuminated in ECL Hyperfilm (GE Healthcare). Because Ab aggregates readily dissociate in the presence of SDScontaining buffers into monomers and small oligomers, such as dimers, trimers, or Ab*56 (Rijal Upadhaya et al., 2012b; Watt et al., 2013) , we analysed differences among the monomer bands that indicate changes in the protein levels of precipitated Ab aggregates densitometrically using ImageJ software (National Institutes of Health).
This method allows a semi-quantitative assessment of Ab as previously described in detail (Rijal Upadhaya et al., 2012a) .
Statistical analysis
SPSS-Statistics 19.0 (SPSS) software was used to calculate statistical tests. One-way ANOVA was used to compare densitometric data received from western blot quantification and Ab loads among cases with Alzheimer's disease, pathologically preclinical Alzheimer's disease and control cases. The Games-Howell post hoc test was used to correct for multiple testing. Binary logistic regression analysis controlled for age and gender was used to test whether dementia was associated with Ab, Ab N3pE , and phosphorylated Ab loads. Partial correlation analysis was performed for Ab-medial temporal lobe phase, Braak-neurofibrillary tangle stage, CERAD score for neuritic plaques, and the biochemical stages of Ab aggregation and accumulation (biochemical-Ab stages) as determined in this study. Likewise, partial correlation analysis controlled for age and gender was also carried out among Abmedial temporal lobe phase, Braak-neurofibrillary tangle stage, CERAD score for neuritic plaques, and a modified biochemical-Ab stage represented by the detection of Ab, Ab N3pE , and phosphorylated Ab in plaques. Fisher's exact test with subsequent trend test was performed to clarify whether the biochemical-Ab stages and biochemical-Ab stage analogues for plaques increase hierarchically with progression of the clinical stage of Alzheimer's disease from nonAlzheimer's disease to pathologically preclinical Alzheimer's disease and finally to symptomatic Alzheimer's disease.
Results
Biochemical detection of soluble, dispersible, membrane-associated and plaque-associated amyloid-b SDS-PAGE and western blot analysis with anti-Ab 1-17 demonstrated Ab in the soluble, dispersible, membrane-associated and plaque-associated fraction in neocortex homogenates from cases Figure 1 Schematic representation of the biochemical fractionation of brain tissue homogenates into soluble, dispersible, membraneassociated SDS-soluble, and plaque-associated (formic acid-soluble) fraction. The dispersible fraction also contains microsomes. Isolation of dispersible oligomers, protofibrils, and fibrils by immunoprecipitation with oligomer or protofibril/fibril-specific antibodies is necessary as previously shown (Rijal Upadhaya et al., 2012a, b) . with Alzheimer's disease and cases with pathologically preclinical Alzheimer's disease. As previously shown Ab dimers, trimers etc. represent SDS treatment-related dissociation products of larger Ab aggregates (Rijal Upadhaya et al., 2012b; Watt et al., 2013) . Therefore, we did not consider them for a separate analysis in this study. The semi-quantitative assessment of the monomer band density has been demonstrated previously to correlate with the amount of Ab aggregates (Rijal Upadhaya et al., 2012a) and was used for the semi-quantitative assessment of Ab aggregates in a given biochemical fraction or being precipitated with A11 and B10AP. Control cases showed no detectable Ab ( Fig. 2A and Supplementary Fig. 1A ). Semi-quantitatively, cases with Alzheimer's disease exhibited significantly more Ab-positive material than cases with pathologically preclinical Alzheimer's disease and non-Alzheimer's disease control cases in all fractions. Pathologically preclinical Alzheimer's disease cases showed more Ab-positive material than non-Alzheimer's disease controls ( Fig. 2A and Supplementary Table 2A) .
Ab N3pE was observed in the soluble, dispersible, membraneassociated and plaque-associated fraction of symptomatic Alzheimer's disease brain homogenates. Cases with pathologically preclinical Alzheimer's disease exhibited no or only small amounts of soluble and dispersible Ab N3pE . SDS-soluble Ab N3pE in the membrane-associated fraction and/or plaque-associated Ab N3pE was detected in 13 of 20 cases with pathologically preclinical Alzheimer's disease by western blotting. Some cases with pathologically preclinical Alzheimer's disease, thereby, exhibited similar amounts of SDS-soluble Ab N3pE as symptomatic cases with Alzheimer's disease ( Fig. 2B and Supplementary Fig. 1B ). Semiquantitative comparison of monomer bands from control, pathologically preclinical Alzheimer's disease and Alzheimer's disease cases revealed that Alzheimer's disease cases exhibited significantly more Ab N3pE in all four fractions than controls and cases with pathologically preclinical Alzheimer's disease. No significant differences in the levels of soluble and plaque-associated Ab were observed between control and pathologically preclinical Alzheimer's disease cases whereas such differences were seen in the dispersible and membrane-associated fraction (Fig. 2B and  Supplementary Table 2A) .
Phosphorylated Ab was found in the dispersible, membraneassociated, and plaque-associated fraction of Alzheimer's disease brain homogenates. Soluble phosphorylated Ab was not observed. Cases with pathologically preclinical Alzheimer's disease did not exhibit detectable levels of phosphorylated Ab in the membraneassociated and plaque-associated fractions. Only isolated pathologically preclinical Alzheimer's disease cases showed few phosphorylated Ab in the dispersible fraction. Phosphorylated Ab was not detected in control cases. A second $8 kDa band was also detected with the phosphorylated Ab antibody. This band presented with similar intensity in soluble, dispersible, and membrane-associated fractions of Alzheimer's disease, pathologically preclinical Alzheimer's disease, and control cases as well as in ischiadic nerve samples ( Supplementary Fig. 3 ). Therefore, we did not interpret this band as a dimer-specific band but as unspecific co-staining without any relevance for Alzheimer's disease because a similar $8 kDa band was not observed in the formic acid-soluble, plaque-associated fraction although dimers were seen (Fig. 2C and Supplementary Fig. 1C ). Significant differences in the semi-quantitative assessment of the phosphorylated Ab monomer bands detected by western blotting were not observed ( Fig. 2C and Supplementary Table 2A) .
To clarify whether the occurrence of Ab N3pE and phosphorylated Ab in Alzheimer's disease and pathologically preclinical Alzheimer's disease cases was related to a specific accumulation in Ab oligomers, protofibrils, and/or fibrils we performed immunoprecipitation and western blotting. Non-fibrillar oligomers were precipitated from soluble and dispersible fractions with A11 antibodies whereas protofibrils and fibrils were precipitated with B10AP antibody fragments. These precipitates contained Ab aggregates as well as oligomeric, protofibrillar, or fibrillar aggregates composed of other proteins (Rijal Upadhaya et al., 2012b) . The highest amounts of oligomeric and protofibrillar/fibrillar Ab aggregates were found in precipitates of the dispersible fraction of Alzheimer's disease cases. Cases with pathologically preclinical Alzheimer's disease had detectable but lower levels of dispersible Ab oligomers, protofibrils, and fibrils than Alzheimer's disease cases. Non-Alzheimer's disease controls did not contain measurable amounts of Ab. The amounts of soluble Ab oligomers, protofibrils, and fibrils did not vary significantly between Alzheimer's disease and pathologically preclinical Alzheimer's disease but were higher in cases with Alzheimer's disease and cases with pathologically preclinical Alzheimer's disease than in controls (Fig. 3A , Supplementary Fig. 2A and Supplementary Table 2B) .
Ab N3pE was not detected in soluble oligomers, protofibrils, and fibrils precipitated with A11 and B10AP but in dispersible oligomers, protofibrils, and fibrils of Alzheimer's disease and pathologically preclinical Alzheimer's disease cases. Non-Alzheimer's disease controls did not display such material. Although dispersible Ab N3pE oligomers, protofibrils, and fibrils appeared to occur in higher levels in Alzheimer's disease neocortex than in pathologically preclinical Alzheimer's disease these differences were not significant (Fig. 3B, Supplementary Fig. 2B and Supplementary Table 2C) .
Dispersible phosphorylated Ab-containing oligomers, protofibrils, and fibrils were found in higher amounts in Alzheimer's disease cases compared to non-Alzheimer's disease controls and pathologically preclinical Alzheimer's disease cases. The amount of dispersible phosphorylated Ab oligomers, protofibrils and fibrils did not vary significantly between non-Alzheimer's disease controls and pathologically preclinical Alzheimer's disease cases. Only a few pathologically preclinical Alzheimer's disease cases exhibited small amounts of phosphorylated Ab-containing protofibrils. Soluble phosphorylated Ab in precipitated oligomers, protofibrils and fibrils was not observed. An 8-kDa band stained with antiphosphorylated Ab was considered unspecific and not relevant for Alzheimer's disease because it was seen in similar intensity in nonAlzheimer's disease controls, pathologically preclinical Alzheimer's disease, symptomatic Alzheimer's disease cases (Fig. 3C , Supplementary Fig. 2C and Supplementary Table 2C ) and in western blots of peripheral nervous tissue of the ischiadic nerve ( Supplementary Fig. 3 ). The fact that it was observed after immunoprecipitation with A11 and B10AP indicates a cross-reaction with components of non-Ab protein complexes sharing A11 and B10AP conformation specific epitopes. analysis of soluble, dispersible, membrane-associated (SDS-soluble) and plaque-associated (formic acid-soluble) fractions of human brain homogenates. Ab was detected with anti-Ab 1-17 . Quantification revealed highest levels of soluble, dispersible, membrane-associated, and plaque-associated Ab in Alzheimer's disease cases whereas pathologically preclinical Alzheimer's disease cases (p-preAD) exhibited lower Ab levels than Alzheimer's disease cases but higher levels than non-Alzheimer's disease controls, which lack detectable amounts of Ab aggregates. (B) Cases with symptomatic Alzheimer's disease exhibited higher levels of soluble, dispersible, membrane-associated and plaque-associated (formic acid soluble) Ab N3pE than pathologically preclinical Alzheimer's disease and control cases. Significant differences occurred between pathologically preclinical Alzheimer's disease and control cases only in the dispersible and membrane-associated fraction. Soluble, dispersible and plaque-associated Ab N3pE was nearly absent in pathologically preclinical Alzheimer's disease cases. SDSsoluble membrane-associated and plaque-associated Ab N3pE was observed in some pathologically preclinical Alzheimer's disease cases whereas other pathologically preclinical Alzheimer's disease cases did not exhibit Ab N3pE distinguishing biochemical-Ab stages 1 and 2. An additional dimer band was visible in the plaque-associated fraction. (C) Phosphorylated Ab was not found in the soluble fraction. In the dispersible, membrane-associated and plaque-associated fractions phosphorylated Ab monomer bands (4 kDa) were visible in cases with Alzheimer's disease exhibiting biochemical-Ab stage 3 whereas most pathologically preclinical Alzheimer's disease cases did not exhibit phosphorylated Ab monomer bands. No significant quantitative differences were observed after western blot analysis. The 8 kDa band stained with anti-phosphorylated Ab was considered unspecific and not relevant for Alzheimer's disease because it was seen in In summary, human Alzheimer's disease brains can be distinguished from non-Alzheimer's disease and pathologically preclinical Alzheimer's disease brains by increasing amounts of soluble and dispersible Ab oligomers, protofibrils, and fibrils whereby phosphorylation of Ab at serine 8 was associated with dispersible Ab oligomers, protofibrils, and fibrils in the Alzheimer's disease neocortex. The biochemical composition of Ab aggregates showed a hierarchical sequence in which Ab, Ab N3pE , and phosphorylated Ab occurred in dispersible, membrane-associated and plaque-associated Ab-aggregates. All 10 cases with Alzheimer's disease and 14 of 20 cases with pathologically preclinical Alzheimer's disease exhibited biochemically detectable Ab. Six cases with pathologically preclinical Alzheimer's disease and the 10 non-Alzheimer's disease cases did not show biochemically detectable amounts of Ab ( Fig. 2A and 3A) . Twelve pathologically preclinical Alzheimer's disease and all 10 Alzheimer's disease cases also showed anti-Ab N3pE -positive material in the Ab aggregates, suggesting a second stage in the development of Ab aggregation. Phosphorylated Ab was found only in 4 of 20 cases with pathologically preclinical Alzheimer's disease, but in all 10 Alzheimer's disease cases studied biochemically in a presumably third stage of this process. These three stages of the biochemical aggregation and accumulation are referred to here as biochemical-Ab stages 1-3.
Immunoprecipitation of post-translational modified Ab N3pE and phosphorylated Ab with subsequent detection of the Ab 40 and Ab 42 C-terminus with C-terminus specific antibodies revealed that Ab N3pE-40 , Ab N3pE-42 , phosphorylated Ab 40 , and phosphorylated Ab 42 can be detected in the human Alzheimer's disease and pathologically preclinical Alzheimer's disease cortex with stronger signals for the Ab 42 -C-terminus peptides ( Supplementary Fig. 4A ).
Immunohistochemical detection of amyloid-b, Ab N3pE and phosphorylated amyloid-b in senile plaques
Immunohistochemical staining of brain tissues from all Alzheimer's disease and pathologically preclinical Alzheimer's disease cases exhibited Ab plaques detectable with antibodies raised against Ab 17-24 and Ab 42 . All cases with Alzheimer's disease and 30 of 33 pathologically preclinical Alzheimer's disease cases also showed immunopositivity for anti-Ab N3pE . Eleven of the pathologically preclinical Alzheimer's disease cases with anti-Ab N3pE positive plaques and all Alzheimer's disease cases also had phosphorylated Ab positive plaques. This hierarchical sequence of plaque staining with anti-Ab 17-24 , anti-Ab N3pE , and anti-phosphorylated Ab was identical with that seen for the biochemical detection of Ab and its accumulation in the dispersible, membrane-associated and plaque-associated fractions of brain homogenates. This sequence of plaque staining is referred to as biochemical-Ab stage analogue for plaques. However, 6 of 20 cases with pathologically preclinical Alzheimer's disease cases with Ab 17-24 -positive plaques (Table 2) did not exhibit significant amounts of biochemically detectable Ab. In two further cases with Ab N3pE -positive plaques Ab was seen biochemically but no Ab N3pE . Four of 16 cases with phosphorylated Ab-positive plaques did not exhibit phosphorylated Ab in the western blot and immunoprecipitation analysis.
Ab plaques detected with antibodies raised against Ab 17-24 and Ab 42 were prevalent in all pathologically preclinical Alzheimer's disease and Alzheimer's disease cases (Fig. 4A-C ). Alzheimer's disease cases exhibited higher Ab loads than pathologically preclinical Alzheimer's disease cases. Non-Alzheimer's disease controls had lower Ab loads than in Alzheimer's disease and pathologically preclinical Alzheimer's disease cases (Fig. 5A and Supplementary  Table 2D ).
Ab N3pE positive plaques were frequently observed in most pathologically preclinical Alzheimer's disease cases and in all Alzheimer's disease cases (Fig. 4D-F ). All types of plaques exhibited Ab N3pE . Ab N3pE plaque loads were lower than total Ab 1-40/42 plaque loads. Alzheimer's disease cases had higher Ab N3pE plaque loads than cases with pathologically preclinical Alzheimer's disease. Cases with pathologically preclinical Alzheimer's disease exhibited higher Ab N3pE plaque loads than non-Alzheimer's disease controls (Fig. 5A and B and Supplementary Table 2D ).
The phosphorylated Ab plaque loads were lower than the Ab and Ab N3pE plaque loads. However, in Alzheimer's disease cases the phosphorylated Ab plaque load was higher than in pathologically preclinical Alzheimer's disease. Non-Alzheimer's disease controls exhibited no anti-phosphorylated Ab-positive plaques whereas some cases with pathologically preclinical Alzheimer's disease showed few phosphorylated Ab-positive plaques. The phosphorylated Ab plaque load in pathologically preclinical Alzheimer's disease cases was slightly higher than in control cases (Figs 4G, H and 5C and Supplementary Table 2D) . Single pathologically preclinical Alzheimer's disease cases exhibiting high amounts of Ab 17-24 and Ab N3pE -positive plaques did not exhibit phosphorylated Ab within these plaques in consecutive sections ( Supplementary Fig. 5 ).
Logistic regression analysis controlled for age and gender revealed a significant association of the Ab load, Ab N3pE load and the phosphorylated Ab load with Alzheimer's disease cases in comparison to cases with pathologically preclinical Alzheimer's disease and non-Alzheimer's disease control cases (P 5 0.05; detailed statistical analysis see Supplementary Table 2E) . Double-label immunohistochemistry revealed that in Alzheimer's disease cases most Ab plaques also exhibit Ab N3pE whereas phosphorylated Ab was usually restricted to a subset of plaques, especially cored plaques ( Supplementary Fig. 4B-J) . Correlations between the biochemical stages of amyloid-b aggregation and accumulation with the hallmark lesions of Alzheimer's disease and its associations with dementia
The biochemical-Ab stages correlated with the Ab-medial temporal lobe phase (r = 0.79, P 5 0.001), the Braak-neurofibrillary tangle-stage (r = 0.609, P = 0.001), and the CERAD score for neuritic plaques (r = 0.56, P = 0.002) as well as with the overall NIA-AA degree of Alzheimer's disease pathology (r = 0.683, P 5 0.001; detailed statistical analysis is shown in Supplementary  Table 2F) .
Likewise, the biochemical-Ab stage analogue for plaques correlated with the Ab-medial temporal lobe-phase (r = 0.834, P 5 0.001), the Braak-neurofibrillary tangle-stage (r = 0.564, P = 0.002), the CERAD score for neuritic plaques (r = 0.429, P = 0.023), the overall NIA-AA degree of Alzheimer's disease pathology (r = 0.76, P 5 0.001; detailed statistical analysis is shown in Supplementary Table 2G ) as well as with the biochemical-Ab stages (r = 0.688, P 5 0.001).
Using Fisher's exact test with a subsequent trend test there was a significant association between the increasing clinical stage of Alzheimer's disease from non-Alzheimer's disease to pathologically preclinical Alzheimer's disease and finally to symptomatic Alzheimer's disease with the biochemical-Ab stage and the biochemical-Ab stage analogue for plaques (P 5 0.001; detailed statistical analysis Supplementary Table 2H ).
Discussion
The major findings of this study are: (i) the prevalence of Ab N3pE and phosphorylated Ab in dispersible, membrane-associated, and plaque-associated Ab aggregates showed a hierarchical sequence of three stages, in which these post-translationally modified Ab species occurred in Ab aggregates: biochemical-Ab stage 1 = aggregation of Ab 1-40/42 alone, biochemical-Ab stage 2 = additional detection of Ab N3pE , and biochemical-Ab stage 3 = aggregation of Ab 1-40/42 , Ab N3pE-40/42 , and phosphorylated Ab 40/42 (Fig. 6); (ii) the phosphorylation of Ab at serine 8 and its aggregation in dispersible oligomers, protofibrils and fibrils was associated with symptomatic Alzheimer's disease but not with pathologically preclinical Alzheimer's disease and controls; (iii) the amounts of soluble and dispersible Ab oligomers, protofibrils and fibrils increased with the development from non-Alzheimer's disease to pathologically preclinical Alzheimer's disease and then to Alzheimer's disease; and (iv) Ab N3pE and phosphorylated Ab were not detectable in soluble oligomers, protofibrils and fibrils but in dispersible ones.
Dispersible, membrane-associated, and plaque-associated Ab aggregates exhibited a hierarchical sequence, in which Ab 1-40/42 , Ab N3pE , and phosphorylated Ab occurred in these aggregates. This sequence allowed the distinction of three biochemical stages of Ab aggregation and accumulation (biochemical-Ab stages). The first stage was characterized by the detection of Ab 1-40/42 in the absence of detectable amounts of Ab N3pE and phosphorylated Ab. Biochemical-Ab stage 2 was characterized by the additional occurrence of Ab N3pE -positive material in these aggregates in the absence of phosphorylated Ab. Phosphorylated Ab in biochemical-Ab stage 3 was restricted to those cases that already exhibited antiAb and anti-Ab N3pE -positive material. Ab N3pE-40 , Ab N3pE-42 , phosphorylated Ab 40 , and phosphorylated Ab 42 were all found in cases with Alzheimer's disease with biochemical-Ab-stage 3. However, Ab N3pE-42 and phosphorylated Ab 42 were the predominant forms. This sequence was further confirmed by the finding of a similar hierarchical sequence in the occurrence of Ab, Ab N3pE , and phosphorylated Ab in senile plaques in controls, cases with pathologically preclinical Alzheimer's disease, and cases with symptomatic Alzheimer's disease. Comparison between biochemical detection of Ab aggregates and immunohistochemistry revealed that the biochemical detection of Ab aggregates by western blotting was less sensitive than immunostaining for plaques. A possible explanation for this finding is that those cases with initial plaque deposition have only very few plaques that may not be included in the samples taken for biochemical analysis or that the amount of plaque-pathology is too low for detection in brain homogenates. The hierarchical staining pattern of plaques and Ab aggregates seen in this study can be explained by either a hierarchical occurrence of these Ab species in the aggregates or by different sensitivities of the antibodies. Arguments in favour of a hierarchical occurrence of Ab 1-40/42 , Ab N3pE and phosphorylated Ab are that the antibody sensitivity of anti-Ab N3pE and anti-phosphorylated Ab were quite similar (Saido et al., 1995; Kumar et al., 2013) and did not explain the differences between biochemical-Ab stages 2 and 3, and that biochemical-Ab stage 1 cases already exhibited significant anti-Ab 1-17 positive material in the absence of Ab N3pE and phosphorylated Ab signals. Moreover, this sequence was seen in Ab aggregates in brain homogenates as well as in plaques stained immunohistochemically with these antibodies. A further argument in favour of a hierarchical sequence in which Ab aggregates accumulate distinct types of Ab peptides is provided by previous reports showing that Ab plaques first stain for Ab 42 , second for Ab 40 (Iwatsubo et al., 1996; Lemere et al., 1996) followed by Ab N3pE (Iwatsubo et al., 1996) , then for Ab N11pE , and, finally, in very few cases, for Ab 17-40/42 (P3) (Iwatsubo et al., 1996;  Figure 3 Continued throughout the pathogenesis of Alzheimer's disease (biochemical-Ab stage 3). The 8 kDa band stained with anti-phosphorylated Ab was considered unspecific and not relevant for Alzheimer's disease because it was seen in non-Alzheimer's disease controls, pathologically preclinical Alzheimer's disease and symptomatic Alzheimer's disease cases in similar intensity. No phosphorylated Ab containing oligomers, protofibrils and fibrils were found in the soluble fraction. Case numbers according to Supplementary Table 1B are provided. Statistical analysis was performed by ANOVA with Games-Howell post hoc test: *P 5 0.05; **P 5 0.01; ***P 5 0.001 (Alzheimer's disease, n = 10; pathologically preclinical Alzheimer's disease, n = 20; control, n = 10; Supplementary Table 2A-C). AD = Alzheimer's disease; B-Ab-stage = biochemical-Ab stage; pAb = phosphorylated Ab; p-preAD = pathologically (diagnosed) Alzheimer's disease. Thal et al., 2005) . As Ab 40 and Ab 42 both occur very early in the development of Ab plaque pathology and as Ab N11pE was seen in plaques of Alzheimer's disease as well as of pathologically preclinical Alzheimer's disease cases, we focused our study on Ab, Ab N3pE and phosphorylated Ab. These three different Ab peptides exhibited a robust hierarchical sequence that provides a backbone for the determination of other peptides and their relation to the development of Alzheimer's disease-related Ab aggregation. A limitation of autopsy studies is that only a single time point can be analysed for each individual. To minimize this limitation we used the Ab phase, the Braak-neurofibrillary tangle stage, and the CERAD score for neuritic plaque pathology as widely accepted pathological markers for Alzheimer's disease progression (Hyman et al., 2012) . The biochemical-Ab stages, thereby, correlated with the phases of Ab plaque distribution (Thal et al., 2002) , the Braakneurofibrillary tangle stages for neurofibrillary tangle distribution (Braak and Braak, 1991) and with the CERAD score for neuritic plaque pathology (Mirra et al., 1991) . This correlation was not simply an effect of ageing because we used partial correlation analysis controlled for age and gender, a statistical method that allows one to calculate the correlation between two parameters independent from age and gender effects. Interestingly, the occurrence and amount of phosphorylated Ab in biochemical-Ab stage 3 cases was associated with symptomatic Alzheimer's disease but not with pathologically preclinical Alzheimer's disease. As such, it is tempting to speculate that the biochemical composition of Ab aggregates changes with the progression of Alzheimer's disease from pathologically preclinical Alzheimer's disease to Alzheimer's disease cases. Hence, we assume that cases with Alzheimer's disease contain more soluble and dispersible Ab oligomers, protofibrils, and fibrils than pathologically preclinical Alzheimer's disease and non-Alzheimer's disease cases and the presence of modified Ab N3pE and phosphorylated Ab peptides may stabilize dispersible oligomeric, protofibrillar and fibrillar Ab aggregates. An argument in favour of this hypothesis is that both Ab N3pE and phosphorylated Ab have the ability to stabilize Ab aggregates (Schlenzig et al., 2009; Kumar et al., 2011 ). An alternative explanation for the increased amounts of Ab N3pE and phosphorylated Ab in Alzheimer's disease cases in comparison with pathologically preclinical Alzheimer's disease cases is that both are by-products of an increased production or decreased clearance of Ab without relevance for the disease and its progression. Accordingly, the accumulation of such by-products would be expected to be more predominant in symptomatic Alzheimer's disease cases compared with pathologically preclinical Alzheimer's disease cases, and Ab N3pE and phosphorylated Ab would accumulate in parallel with Ab plaques detected with anti-Ab 17-24 or antiAb 42 . However, this was not the case for phosphorylated Ab. As depicted in Supplementary Fig. 5 isolated pathologically preclinical Alzheimer's disease cases exhibited very high amounts of Ab [17] [18] [19] [20] [21] [22] [23] [24] and Ab N3pE -positive plaques, even more than some Alzheimer's disease cases, but no phosphorylated Ab. On the other hand, phosphorylated Ab was seen in all symptomatic Alzheimer's disease cases, even in those that had fewer plaques than some pathologically preclinical Alzheimer's disease cases. Another argument against the hypothesis that Ab N3pE and phosphorylated Ab are by-products of Ab accumulation without specific impact on the disease is that both modified forms of Ab are more prone to form oligomeric and fibrillar aggregates in vitro than non-modified Ab (Saido et al., 1995; Schlenzig et al., 2009; Kumar et al., 2011) . As such, Ab N3pE and phosphorylated Ab promote the formation of oligomeric, protofibrillar and fibrillar aggregates of Ab and the biochemical-Ab stages more likely document the biochemical development of Ab aggregates in the pathogenesis of Alzheimer's disease. For all that, it is not yet clear whether Ab N3pE and phosphorylated Ab play a directing role in the pathogenesis of Alzheimer's disease. At least, they serve as marker proteins for the progression of the disease as shown here.
It is important to note that the biochemical development of Ab aggregates starts with the aggregation of Ab in all four fractions received after brain homogenization. Immunoprecipitation with B10AP antibody fragments and A11 revealed that these initial Ab aggregates already contain Ab oligomers, protofibrils and fibrils. Given the sequence of events in the biochemical-Ab stages, it is tempting to speculate that modification of initial Ab aggregates by adding detectable amounts of Ab N3pE and phosphorylated Ab The Ab N3pE load in pathologically preclinical Alzheimer's disease and Alzheimer's disease cases was higher than in non-Alzheimer's disease cases. Significant differences in the Ab N3pE load between pathologically preclinical Alzheimer's disease and Alzheimer's disease cases were not observed. (C) Alzheimer's disease cases had significantly higher phosphorylated Ab loads compared with control and pathologically preclinical Alzheimer's disease cases. ANOVA with Games-Howell post hoc test: *P 5 0.05; ***P 5 0.001 (Supplementary Table 2E ). AD = Alzheimer's disease; pAb = phosphorylated Ab; p-preAD = pathologically (diagnosed) Alzheimer's disease.
Biochemical stages of Ab deposition
Brain 2014: 137; 887-903 | 899 peptides to these aggregates is a critical event for the development of Alzheimer's disease. Phosphorylation of Ab at serine 8 indicating biochemical-Ab stage 3 rather than the mere presence of Ab N3pE , thereby seems to be critical for conversion from pathologically preclinical Alzheimer's disease to Alzheimer's disease. Arguments in favour of this hypothesis are: (i) pathologically preclinical Alzheimer's disease cases do not exhibit significant amounts of phosphorylated Ab in dispersible oligomers, protofibrils and fibrils but Alzheimer's disease cases do; (ii) cases with Alzheimer's disease have significant numbers of phosphorylated Ab-containing plaques (phosphorylated Ab plaque load = 1.21%) whereas the phosphorylated Ab plaque load was in mean 50.28% in pathologically preclinical Alzheimer's disease cases; and (iii) Ab N3pE is already present in significant amounts in plaques (Ab N3pE plaque load = 2.25%), dispersible oligomers, protofibrils, fibrils, and in the SDS-soluble membrane-associated fraction in pathologically preclinical Alzheimer's disease cases and increases quantitatively in Alzheimer's disease (Ab N3pE plaque load = 4.22%) but does not indicate a qualitative change in the composition of Ab aggregates between Alzheimer's disease and pathologically preclinical Alzheimer's disease cases because Ab N3pE already occurs in biochemical-Ab stage 2, which is seen in pathologically preclinical Alzheimer's disease cases, and in biochemicalAb stage 3 in Alzheimer's disease cases. In the event that phosphorylation of Ab increases its tendency to form dispersible aggregates and, thereby, supports conversion from pathologically preclinical Alzheimer's disease to Alzheimer's disease, blocking or modulation of Ab phosphorylation would be an appropriate mechanism to prevent or delay the conversion from pathologically preclinical Alzheimer's disease to symptomatic Alzheimer's disease. An aggregation promoting the role for phosphorylated Ab has been demonstrated (Kumar et al., 2011) . However, it is important to Figure 6 Associations between the diagnosis of Alzheimer's disease, pathologically preclinical Alzheimer's disease and control cases with the biochemical-Ab stages of the biochemical composition of Ab aggregates and with the Ab-medial temporal lobe phases. 'NonAlzheimer's disease' is by definition the absence of Ab plaques. Pathologically preclinical Alzheimer's disease cases and cases with symptomatic Alzheimer's disease can be distinguished by the distribution of Ab plaque pathology in the brain as represented in the medial temporal lobe (Thal et al., 2000 (Thal et al., , 2002 (Thal et al., , 2013 but also by changes in the biochemical composition of soluble, dispersible, membraneassociated, and plaque-associated Ab aggregates as represented by the biochemical-Ab stages. These differences in the biochemical composition of Ab aggregates between cases with pathologically preclinical Alzheimer's disease and Alzheimer's disease cases are indicated by the detection of phosphorylated Ab in symptomatic Alzheimer's disease cases and by the detection of Ab N3pE in the soluble and dispersible fraction. The hierarchical sequence, in which Ab 1-40/42 , Ab N3pE , and phosphorylated Ab occurred in the Ab aggregates in the human brain, thereby, allowed the distinction of three biochemical-Ab stages: biochemical-Ab stage 1 was defined by the detection of anti-Ab-positive Ab aggregates in the absence of detectable amounts of Ab N3pE and phosphorylated Ab; biochemical-Ab stage 2 was characterized by additional Ab N3pE in the aggregates without detectable phosphorylated Ab; biochemical-Ab stage 3 represented Ab aggregates in the brain exhibiting all three types of Ab, i.e. Ab 1-40/42 , Ab N3pE , and phosphorylated Ab. AD = Alzheimer's disease; AbMTL phase = Ab medial temporal lobe phase; B-Ab-stage = biochemical-Ab stage; pAb = phosphorylated Ab; p-preAD = pathologically (diagnosed) Alzheimer's disease. test this potential treatment strategy in an appropriate animal model to exclude the possibility that phosphorylated Ab is merely a by-product of the disease without therapeutic potential.
Phosphorylation of serine residues by protein kinase A similar to serine 8 of the Ab peptide (Kumar et al., 2011) is also seen in tau protein (Andorfer and Davies, 2000) . Thus, one could assume that Ab and tau phosphorylation are two results of a common problem: increased phosphorylation of proteins in the Alzheimer's disease brain. Arguments against this hypothesis are that: (i) dispersible Ab alone was associated with neurodegeneration in APP transgenic mice with an increased Ab production (Rijal Upadhaya et al., 2012a); (ii) Ab was capable of exacerbating tau pathology in tau transgenic mice (Gotz et al., 2001; Lewis et al., 2001) suggesting a causative or at least triggering role for Ab in Alzheimer's disease-related neurodegeneration; and (iii) tau phosphorylation occurs early in the pathogenesis of neuronal alterations in Alzheimer's disease (Braak et al., 2011) as well as in other nonAlzheimer's disease tauopathies (Dickson et al., 2011) , whereas Ab phosphorylation at serine 8 is a late event mainly restricted to symptomatic Alzheimer's disease cases, as shown here.
As Ab N3pE and phosphorylated Ab have also been found in APP/PS1 transgenic mice without inducing significant levels of tau pathology the hierarchical accumulation of different forms of Ab peptides alone may not cause Alzheimer's disease, but in the presence of mild, pre-existing tau pathology as it is regularly the case in elderly humans (Braak et al., 2011) , Ab aggregates may exacerbate tau pathology as also seen in mouse models for Alzheimer's disease (Gotz et al., 2001; Lewis et al., 2001; Oddo et al., 2004) .
Our finding, that soluble and dispersible Ab oligomers, protofibrils and fibrils increase from pathologically preclinical Alzheimer's disease to Alzheimer's disease cases is in line with the previously reported detection of Ab oligomers, protofibrils and fibrils in Alzheimer's disease cases (Kayed et al., 2003; Habicht et al., 2007; Mc Donald et al., 2010) . However, our data apparently contradict reports by other authors showing that the Ab plaque loads did not vary significantly between Alzheimer's disease and non-demented cases with plaque pathology (Arriagada et al., 1992b) and that increasing cognitive decline in patients with Alzeimer's disease could not be explained by differences in the Ab loads (Arriagada et al., 1992a) . Of note, in the present study, some pathologically preclinical Alzheimer's disease cases had higher amyloid plaque loads in the temporal neocortex than some cases with Alzheimer's disease ( Supplementary Fig. 5 ). This might explain the lack of statistically significant differences in Ab loads reported in the abovementioned studies. However, when staining Ab plaques for phosphorylated Ab we found significant differences between pathologically preclinical Alzheimer's disease and Alzheimer's disease cases in the respective phosphorylated Ab plaque loads indicating that changes in the biochemical composition of the Ab aggregates occur when pathologically preclinical Alzheimer's disease cases convert to symptomatic Alzheimer's disease, i.e. the conversion from biochemical-Ab stage 2 to biochemical-Ab stage 3. These qualitative changes were also found biochemically in dispersible Ab oligomers, protofibrils, and fibrils as well as in the membrane-associated and plaque-associated fractions.
Although it is tempting to assume that the hierarchical sequences of Ab plaque distribution and that of the biochemical evolution of Alzheimer's disease-related Ab aggregates represent a pathogenetic sequence of events it is possible that this sequence can be held at a given point or that Ab deposition is even reversible until a given point in this sequence. Accordingly, cases classified as pathologically preclinical Alzheimer's disease (nondemented individuals with Alzheimer's disease pathology according to current NIA-AA criteria for the neuropathological diagnosis of Alzheimer's disease (Hyman et al., 2012) ) do not necessarily develop symptomatic Alzheimer's disease.
The non-Alzheimer's disease control and pathologically preclinical Alzheimer's disease cases included in this study were identified at autopsy and were not tested for Alzheimer's disease biomarkers, such as CSF-Ab and CSF-tau protein or amyloid PET. Therefore, the pathologically preclinical Alzheimer's disease cases in our study cannot be compared with clinically detectable preclinical Alzheimer's disease cases according to Vos et al. (2013) . However, it will be an important issue for future research to verify the neuropathological and biochemical correlatives in amyloid PET-positive or CSF-biomarker positive non-demented cases and to distinguish them from cases with symptomatic Alzheimer's disease and non-Alzheimer's disease.
The missing signals for Ab N3pE and phosphorylated Ab in the soluble oligomers, protofibrils, and fibrils argue in favour of aggregation promoting effects of both post-translational modified Ab species as previously described in vitro (Schlenzig et al., 2009; Kumar et al., 2011) . However, Ab N3pE was observed in the soluble fraction of Alzheimer's disease cases indicating that presumably smaller Ab N3pE oligomers are present in the Alzheimer's disease brain that cannot be precipitated with A11 and B10AP.
In conclusion, we have shown qualitative differences in the composition of Ab plaques and dispersible Ab oligomers, protofibrils and fibrils between Alzheimer's disease and pathologically preclinical Alzheimer's disease cases that allow the distinction of three biochemical-Ab stages. Although it appears quite obvious that non-phosphorylated full-length Ab accumulates before truncated and phosphorylated forms become detectable, their sequence of occurrence was associated with a critical step in the pathogenesis of Alzheimer's disease: phosphorylated Ab, indicative for biochemical-Ab stage 3, was specifically associated with symptomatic Alzheimer's disease. Thus, phosphorylated Ab may support further accumulation of Ab oligomers, protofibrils, and fibrils in the event that pathologically preclinical Alzheimer's disease converts into Alzheimer's disease. Phosphorylation of Ab at serine 8 may be a new therapeutic target to prevent conversion from pathologically preclinical Alzheimer's disease to Alzheimer's disease.
